-
公开(公告)号：US20240301063A1
公开(公告)日：2024-09-12
申请号：US18671707
申请日：2024-05-22
发明人： Qiang Li , Shixiang Jia , Lili Zhao , Guimin Zhang , Zhong Liu , Xinlu Ma , Yuan Yan , Zhenyu Li , Xingxia Hu , Yuhua Zhang , Bin Li
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/30 , C07K16/32 , C07K16/46 , C12N15/62 , C12N15/85
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , A61P35/00 , C07K16/2803 , C07K16/2863 , C07K16/2878 , C07K16/2887 , C07K16/3007 , C07K16/303 , C07K16/32 , C07K16/468 , C12N15/62 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.
-
2.发明公开公开(公告)号：US20240285712A1
公开(公告)日：2024-08-29
申请号：US18573183
申请日：2022-06-27
发明人： Guimin Zhang , Xin Li , Dongguang Liu
IPC分类号： A61K36/538 , A61K36/07 , A61K36/23 , A61K36/232 , A61K36/233 , A61K36/236 , A61K36/237 , A61K36/238 , A61K36/28 , A61K36/484 , A61K36/752 , A61P11/06
CPC分类号： A61K36/538 , A61K36/07 , A61K36/23 , A61K36/232 , A61K36/233 , A61K36/236 , A61K36/237 , A61K36/238 , A61K36/28 , A61K36/484 , A61K36/752 , A61P11/06 , A61K2236/333 , A61K2236/39
摘要： A traditional Chinese medicinal composition is prepared from Herba schizonepetae, Radix saposhnikoviae, Notopterygium root, Radix angelicae pubescentis, Radix bupleuri, common hogfennel root, Rhizoma chuanxiong, Fructus aurantii, Poria cocos, Radix platycodonis, and liquorice root. The traditional Chinese medicinal composition can reduce the cough frequency of a guinea pig model with cough variant asthma, a percentage of eosinophils in a bronchoalveolar lavage fluid, and a level of serum eosinophil cationic proteins, and has a prevention and treatment effect on the cough variant asthma.
-
公开(公告)号：US12030939B2
公开(公告)日：2024-07-09
申请号：US17290401
申请日：2019-09-26
发明人： Qiang Li , Shixiang Jia , Lili Zhao , Guimin Zhang , Zhong Liu , Xinlu Ma , Yuan Yan , Zhenyu Li , Xingxia Hu , Yuhua Zhang , Bin Li
IPC分类号： C07K16/30 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/28 , C07K16/32 , C07K16/46 , C12N15/62 , C12N15/85 , A61K39/00
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , A61P35/00 , C07K16/2803 , C07K16/2863 , C07K16/2878 , C07K16/2887 , C07K16/3007 , C07K16/303 , C07K16/32 , C07K16/468 , C12N15/62 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.
-
公开(公告)号：US20230416385A1
公开(公告)日：2023-12-28
申请号：US17290401
申请日：2019-09-26
发明人： Qiang Li , Shixiang Jia , Lili Zhao , Guimin Zhang , Zhong Liu , Xinlu Ma , Yuan Yan , Zhenyu Li , Xingxia Hu , Yuhua Zhang , Bin Li
CPC分类号： C07K16/2878 , C07K16/2809 , A61P35/00 , A61K2039/505 , C07K2317/622 , C07K2317/33 , C07K2317/31
摘要： A bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests. The method for constructing a bispecific antibody is simple, and avoids the possibility of mismatching between two sets of light chains and heavy chains of a heterologous bispecific antibody, thus the difficulty of antibody purification is reduced, the affinity of the obtained antibody is high, the side effects of induced cytokines are few, and safety is high.
-
-
-
搜索结果
4 条记录 (耗时 0.02 秒)
